Key result
Novel therapies such as sacubitril/valsartan and ivabradine have recently been approved for heart failure, while other agents like potassium binders and relaxin show promise in ongoing trials.
This review highlights the recent FDA approvals of sacubitril/valsartan and ivabradine for heart failure, alongside promising emerging therapies for hyperkalemia and acute heart failure.
May inform heart failure guideline updates; leaves open optimal sequencing and comparative effectiveness of emerging agents.
With the total cases and economic burden of heart failure continuing to rise, there is an overwhelming need for novel therapies. Several drugs for heart failure have succeeded in preclinical and early-phase clinical trials, but most of them failed to show the real benefit in pivotal clinical trials. Meanwhile, the US Food and Drug Administration recently approved two promising new drugs to treat heart failure: ivabradine and sacubitril/valsartan. Furthermore, some of the newer agents in testing offer the potential for significant progress in addition to these drugs. Patiromer and zirconium cyclosilicate are attractive agents that are expected to prevent hyperkalemia during renin-angiotensin-aldosterone system inhibition, and serelaxin and urodilatin are promising drugs in the treatment of acute heart failure. Future clinical trials with more appropriate study designs, optimal clinical endpoints, and proper patient selection are mandatory to assess the true efficacy of these attractive compounds in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kitai et al. (2015) conducted a review in Heart failure. Novel heart failure therapies (e.g., sacubitril/valsartan, ivabradine) vs. Standard of care or placebo was evaluated. Novel therapies such as sacubitril/valsartan and ivabradine have recently been approved for heart failure, while other agents like potassium binders and relaxin show promise in ongoing trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: